Get started
AMGEN INCAMGEN INCAMGEN INC

AMGEN INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

AMGN trade ideas

Long? Yes I Am-genNothing revolutionary here today, just an algo call on a stock that has been a solid performer for me historically. The rationale: --In a trading range longer term, but a short/medium term uptrend --right at short term support level --1313-1* W/L record with my algo (the 1 being 2 days ago and still would be open) --Avg. gain per trade is just over 2% ---Avg daily return is about 2.5x that of stocks in general, long term Initial entry was at 305.70. Per my usual strategy, I'll add to my position at the close on any day it still rates as a “buy” and I will use FPC (first profitable close) to exit any lot on the day it closes at any profit. As always - this is intended as "edutainment" and my perspective on what I am or would be doing, not a recommendation for you to buy or sell. Act accordingly and invest at your own risk. DYOR and only make investments that make good financial sense for you in your current situation.
NASDAQ:AMGNLong
by redwingcoach
1
AMGEN Nearing a Breakout—Is It Time to Act?Is AMGN on the Verge of a Major Move? With Amgen Inc. (NASDAQ: AMGN) currently trading at $287.38, the stock is hovering close to key resistance at $294.65, a level that could dictate its next big move. Despite sitting 17% below its historical high of $346.85, AMGN has rallied significantly from its absolute low of $211.71, reflecting a 35% rebound. Technical indicators suggest the stock is approaching a crucial inflection point. The RSI14 at 59.99 shows the stock is nearing overbought conditions but hasn't crossed the threshold yet, while the MFI at 64.63 hints at strong money flow. Moving averages are aligned bullishly, with MA50 at $283.00, MA100 at $279.02, and MA200 at $272.19, all supporting the uptrend. However, recent "Sell Volumes Take Over" patterns indicate increased selling pressure near highs, creating potential short-term volatility. Will buyers absorb the selling and push AMGN through resistance, or is the stock setting up for a reversal? With macroeconomic uncertainty and biotech sector sentiment playing a role, this could be a make-or-break moment for AMGN traders and investors. The big question—are you positioned for what’s next? AMGN Price Roadmap: Decoding Market Moves Step by Step Tracking AMGN’s price action through pattern recognition gives traders an edge in predicting potential moves. Let’s break down the most relevant patterns that played out successfully, confirming their main direction. 1. January 27, 2025 - Buy Volumes Take Over (Sell Direction Ignored) Price opened and closed at $282, but despite a 6.35% range, the bearish move wasn't confirmed. Instead, we saw an influx of Buy Volumes Max just hours later, setting the stage for an upward move. 2. January 28, 2025 - Increased Buy Volumes (Confirmed Uptrend) The Buy Volumes Max pattern held strong, with price climbing to a high of $283.22 before consolidating. This confirmed that the previous sell pattern failed, while buyers took control. 3. January 31, 2025 - Sell Volumes Take Over (Bearish Shift Confirmed) Price action showed heavy selling pressure, with a range of $285.42 - $287.11. The next pattern, Increased Sell Volumes, validated the bearish momentum, confirming a 4.71% decline shortly after. 4. February 1, 2025 - Increased Sell Volumes (Downtrend Holds) The continuation of high sell volumes pushed AMGN down to $284.92, confirming a successful transition from the previous Sell Volumes Takeover pattern. Traders caught in longs at resistance likely got shaken out, while aggressive sellers dominated the flow. What’s Next? With AMGN testing key resistance near $287, the next pattern will be crucial. A break above resistance could invalidate the current bearish structure, while a failure to hold recent highs could send price back toward the $280 zone. Watch the order flow carefully—the next move could be explosive. Technical & Price Action Analysis: Key Levels to Watch In trading, levels are everything. If a support doesn’t hold, it flips into resistance—same story in reverse. Here’s what we’re watching right now on AMGN: Support Levels to Catch a Bid 259.29 – First real demand zone; buyers need to step in here. 252.45 – If this level doesn’t hold, expect liquidity grabs below. 251.47 – Close to the danger zone, where panic selling could accelerate. 248.56 – Bulls’ last line of defense before a major flush. 231.50 – If we see this, something bigger is at play. Resistance Levels That Must Break for Upside 294.65 – First stop for any real breakout traders. 300.00 – Psychological round number, algos are watching. 318.54 – Mid-term target if we get momentum. 328.35 – A key pivot for long-term positioning. 330.92 – Break above here, and we’re in new territory. Power Levels – Where Big Money Is Positioned Support that Must Hold: 297.91 – If lost, could act as strong resistance on retest. 325.91 – Major liquidity zone, failure here signals deep correction. 333.15 – Last line before heavy trend Trading Strategies Based on Rays: Key Scenarios & Setups The VSA Rays mapped on the chart serve as the foundation for our trading framework. These Fibonacci-based dynamic levels define zones of interaction, where price has two choices—continue the trend or reverse. Positions should only be considered after price interaction with the rays and the confirmation of a directional move. Each price move progresses from ray to ray, establishing first, second, and third targets for trades. Moving Averages further refine these levels, acting as dynamic support and resistance zones. 📈 Optimistic Scenario: Trend Continuation & Breakout Play If price successfully interacts with the MA50 ($283.00) and MA100 ($279.02) and bounces off a VSA ray, we are looking at a bullish continuation. First target: $294.65 (Initial breakout zone) Second target: $300.00 (Psychological and technical resistance) Third target: $318.54 (Longer-term target for swing traders) Key trigger: Confirmation above the breakout ray + moving average support. A strong close above these levels increases the probability of a trend continuation. 📉 Pessimistic Scenario: Rejection & Breakdown Play If price interacts with $294.65 but fails to break through, then a reversal setup is in play. First target: $259.29 (Initial support zone) Second target: $252.45 (Key demand level) Third target: $231.50 (Bearish exhaustion zone) Key trigger: Rejection at resistance ray + moving average failure. If price fails to hold MA50 ($283.00) or MA100 ($279.02), it signals a deeper correction. 🔥 Trade Setups Based on Key Levels Breakout Buy above $294.65 → Target $300.00, $318.54 Reversal Short from $294.65 → Target $283.00, $259.29 Bounce Buy from $259.29 → Target $294.65, $300.00 Sell on Breakdown below $259.29 → Target $252.45, $231.50 Resistance That Could Reject Hard: 244.25 – Hidden selling pressure waiting above. 227.79 – Institutional sell wall if price wicks up. If these support levels get sliced through, expect them to flip into resistance, trapping weak hands and fueling the next move. Keep stops tight—this game isn’t for the faint-hearted. 🚀 Let’s Talk Trading – Drop Your Comments Below! Markets move, but precision matters—and that’s why you should save this idea and check back later to see how price respects my levels. If you find these insights useful, hit that Boost button and let’s keep tracking the moves together! 📈 Got questions? Want to discuss a setup? Drop them in the comments—I always check and answer! And if you have a specific asset you’d like analyzed, let me know. Some ideas I can share publicly, while others we can keep private, depending on what you need. My ray-based strategy maps out all key levels automatically, but it’s only available in Private. If you’re interested in using it, just send me a DM. Trust me, once you see how price follows the rays, you’ll never trade the same way again. The best part? These levels work on any asset. If you want a custom markup—just say the word. Let me know which tickers you’re watching, and I’ll add them to my list for upcoming analyses. More Boosts = more priority! And of course, if you’re new here, follow me on TradingView to stay updated on fresh ideas. Smart trading is all about being in the right place at the right time. Let’s catch these moves together! 🚀🔥
NASDAQ:AMGNLong
by brandlabelden
$AMGN observationThis is just my observation, not advice. Technical: 1. Price touched the 200 SMA. 2. Price is corrected to 50% correction and slightly pumped after reaching the supportive zone. 3. Price reached the volume price of FRVP around 270$. 4. The correction nature of the latest candles in the blue box is obvious. 5. In the daily and 4H charts, the stock is almost in the oversold zone. 6. A significant divergence is observable on the daily chart. Fundamental: 1. P/E ratio: 34.4x (Not undervalued) 2. In November 2024, Amgen's Phase 2 study of MariTide showed a 20% average weight loss over 52 weeks in obese patients without diabetes. While promising, it fell short of analysts' 23–25% expectations, raising concerns about its competitiveness against treatments like Eli Lilly's Zepbound and Novo Nordisk's Wegovy. 3. On November 26th, after MariTide phase 2 announcement, the price was mixed but could be considered to have moved up impulsively. 4. On 5th December, Amgen announced to invest 1B for expansion. 5. NASDAQ:AMGN launched Pavblu as a rival of NASDAQ:REGN 's Eylea. 6. On December 7th, NASDAQ:AMGN out significant result for Blinatumomab. 7. Based on reports, NASDAQ:AMGN raises quarterly dividend 5.8%. 8. Analyst sentiments: 14 buy, 15 hold, 3 sell. Scenarios: We are in the correction with two main scenarios: 1. ABC correction has been completed and impulsive waves have been started so we should look for entry. 2. A correction wave has been completed, and we are now in the B wave correction. In this case, we should see another price drop on wave C. After then, we can look for long on around 78% correction and trendline.
NASDAQ:AMGNLong
by jack_the_real_trader
AMGNThe analysis of the stock you mentioned (AMGN) Daily Frame suggests the presence of a rising wedge pattern, indicating a potential price correction after a false breakout. Here’s a breakdown of the points mentioned: Rising Wedge Pattern: This type of pattern typically appears in bullish markets, but it can turn into a bearish reversal if the lower boundary of the wedge is broken. False Breakout: A false breakout occurs when the stock briefly exceeds the upper boundary of the pattern but fails to sustain the upward momentum, leading to a price correction. If the lower boundary of the wedge is confirmed to be broken, this could signal the beginning of a downtrend. Breaking the Rising Wedge: A confirmed break of the wedge suggests that the upward trend is over or may be in the process of reversing into a downward trend. Sell from the Next Session: Based on this technical analysis, the plan is to enter a short position (sell) with a stop loss if the price rises above $338.5, which is identified as the upper resistance level. Price Target: The suggested support levels where the stock could potentially drop to are between $213.64 and $203.
NASDAQ:AMGNShort
by IbrahimTarek
Amgen: False Breakdown and Uptrend?Amgen has been fighting higher this year, and some traders may think a longer-term uptrend is in place. The first pattern on today’s chart is the move under $310 after mixed quarterly results. The drugmaker quickly recovered as Wall Street focused on its pipeline. The resulting drop and rebound could be viewed as a “false breakdown,” which is potentially bullish. Next is the price zone between the closing highs of February and June. AMGN has stayed above that area for almost two weeks. Has old resistance become new support? It’s also holding the rising 50-day simple moving average. That could reflect a bullish intermediate-term trend. Finally, Wilder’s Relative Strength Index (RSI) just crossed above its 14-day average. Similar crossovers have preceded moves in both directions. (See arrows.) TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NASDAQ:AMGN
by TradeStation
AMGN - Increased Probability of AppreciationAMGN has the support of Fiboclouds indicating an increased probability of appreciation at least until the first target. The second target should be tested, provided the stop loss is properly repositioned at the time of the first partial realization. If this projection is confirmed and a partial realization occurs at the first target, the stop loss should be moved from its initial position to the same line where the position was opened. This way, the journey towards the final target will proceed with reduced risk of losses and the preservation of the partial gains achieved so far. Follow us to receive notifications of new trades as well as frequent updates on ongoing trades. Finally, if you agree with the idea or found it useful, please give it a BOOST so that it can reach a larger number of people! Thank you!
NASDAQ:AMGNLong
by EthosInvest
Buyback Patterns for Swing TradingNASDAQ:AMGN shows a buyback run followed by a sell day that was instigated by market makers as buyers quickly disappeared. Remember that corporate buybacks are done by bank floor traders to add stock to their inventory so they won't take profits at the peak of the run; those are other market participants, such as market makers. NYSE:KO is another example of a buyback run and how price moves back down after the professionals conclude their buybacks. The buybacks were announced in May this year so this stock has just started its share repurchase program.
NASDAQ:AMGN
by MarthaStokesCMT-TechniTrader
AMGN Puts 290 Strike August 16th Expiration.I believe "AMGN" will get to around 217.7ish and then dip. From a technical viewpoint I believe its showing a "head and shoulders top" based on a chart that looks back since August of 2023. I am a rookie and don't know if this is true but am basing it on that. From a fundamental viewpoint I believe the stocks rise is all a bunch of garbage. The market is bullish over the weight-loss market and are rushing into any idea in biotech that may work. Its tempting to do this because of how Eli Lilly has been historically strong, while everything else in its sector is basically garbage. My stop loss would be at above 322ish and my profits would start being taken under 300. They report earnings in week of August 1 to August 5. Detail of Potential Trade Enter Target: 317.7 Strike: 290 Expiration: AUG 16th Current Premium as of Publish: 4.2
NASDAQ:AMGNShort
by aminneil43002
Amgen's MariTide Shakes Up Weight Loss Drug MarketThe weight loss drug market, projected to hit $100 billion by the decade's end, is undergoing significant innovation. Amidst dominant players like Novo Nordisk and Eli Lilly, Amgen is emerging with MariTide, a potentially game-changing drug set to disrupt the industry. MariTide's extended-release formula promises reduced dosing frequency and sustained weight loss, potentially outperforming current medications. Amgen's advantage lies in its robust manufacturing infrastructure, enabling efficient scaling compared to smaller competitors. However, the field is crowded, with Novo Nordisk and Eli Lilly developing next-gen drugs, while Boehringer Ingelheim and others introduce new contenders. Smaller biotechs like Viking Therapeutics and Altimmune are also advancing innovative solutions. This competitive landscape promises diverse and effective weight management options for patients. The future looks bright, with Amgen positioned as a strong buy in this evolving market.
NASDAQ:AMGNLong
by signalmastermind
AMGN Rises as CEO Celebrates Growth in Experimental Obesity DrugAmgen Inc.'s shares ( NASDAQ:AMGN ) rose by 15.9% when the market opened on Friday, marking its biggest intraday rise since July 2009. The company has emerged as a potential competitor to Eli Lilly & Co. and Novo Nordisk A/S, which currently dominate the weight-loss market. Demand for anti-obesity drugs like Zepbound and Wegovy is so strong that Intelligence's estimate for $80 billion in annual sales by 2030 looks conservative. William Blair analyst Matt Phipps sees MariTide as having multi-blockbuster potential, boosting his rating on Amgen stock to outperform. Shares of Denmark's Novo Nordisk fell as much as 5.3% after the Amgen CEO's comments. Optimism over towering sales of its Wegovy and Ozempic drugs have pushed Novo's market value above $500 billion, reinforcing its position as Europe's most valuable listed company. The stock has more than quadrupled since the start of 2020. MariTide has excited investors because it's taken less frequently than the top-selling treatments from Novo and Lilly. Patients given a monthly injection of the drug lost up to 14.5% of their body weight in 12 weeks, according to a small early-stage study published in February in the journal Nature Metabolism. Some people kept weight off for up to 150 days after stopping the drug, the findings showed. Amgen ( NASDAQ:AMGN ) is already investing in building out production capacity for MariTide, even though it's still in mid-stage studies and hasn't been submitted for regulatory approval. Amgen is planning late-stage studies in obesity, obesity-related conditions, and diabetes, likely delivered in a handheld autoinjector used monthly. Amgen will focus on MariTide and discontinue developing another earlier-stage drug called AMG 786.
NASDAQ:AMGNLong
by DEXWireNews
Can Amgen(NASD:AMGN) shares go significantly higher?The Minichart Trendline indicator has determined that the share price of Amgen Inc. has just broken its downtrend and is likely to recover from here. This indicator developed by Minichart can detect stocks that change their trend, either from an uptrend to a downtrend or vice versa. It is plotted automatically. First of all, Amgen Inc. stock price reached a short-term support 2 days ago when it hit the 38.2% Fibonacci support of a strong uptrend. The uptrend of the stock price started on 1 June 2023, and lasted for 7 months. The strong uptrend has also formed a bullish head and shoulders (H&S) formation on the Minichart. From a technical analysis perspective, the recent pullback is a salutary correction after the price broke out of the H&S formation. Over time, the price will probably continue to rise and break above the high reached on February 5. In addition, there are 3 other reasons why the price may have reached a good support and could rise again from here. The price has reached the exponential moving average of 100. This is a strong support level. The Minichart Heikin Ashi indicator has changed colour. It is now bullish. The Stochastic indicator is oversold and starting to turn upwards. Amgen Inc. Price Target Next, we will use the Fibonacci retracement to find the immediate price target when the price starts to recover. Using the Minichart Fibonacci retracement measurement from February 5 to 20, the first price target is $299, followed by $305. This is based on the 38.2% to 50% Fibonacci retracement levels. These levels coincided with resistance points during the sideways consolidation (green arrow on the chart). If traders were to buy the stock based on Friday’s close of $289.18, they could potentially realise a decent return of 3.5% to 5.5%. This is based on the $299 to $305 Minichart price target mentioned above. Of course, this is a short-term price target that can be reached within the next few weeks. Should the share price break through the high reached on February 5, the new price target will be significantly higher.
NASDAQ:AMGNLong
by minichartsg
Amgen Poised for Continued Upside## Amgen Poised for Continued Upside Amgen Inc. (AMGN) appears poised for continued upside based on technical indicators. The current price of $324.56 is above the 50-day and 200-day simple moving averages, indicating an upward trend. Key technical indicators also suggest further upside: - Relative Strength Index (RSI) of 66 indicates AMGN is not overbought and has room to run - Moving Average Convergence Divergence (MACD) line recently crossed above the signal line in a bullish sign - Bollinger Bands widening suggests building upside momentum I am initiating a buy on AMGN with an entry point of $330.95. This allows some room above the current price for confirmation of the uptrend. Profit targets are set at $340.79, while a stop loss of $321.36 limits downside risk. The positive technical outlook combined with strong fundamentals makes AMGN a compelling buy at current levels for continued price appreciation. I will look to take profits as the price approaches overbought levels near the upper Bollinger Band. Managing risk with the defined stop loss is also key to success of this long setup. Citations: www.investing.com www.chartmill.com www.macroaxis.com www.tipranks.com financhill.com
NASDAQ:AMGNLong
by decisioncrafters